444646-72-4

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 649722-53-2 4-[1-allylamino-3-(t-butyl-diphenyl-silanyloxy)-1-hydroxy-propyl]-3-vinyl-phenyl dimethylcarbamate 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 649722-52-1 4-[1-bromo-3-(t-butyl-diphenyl-silanyloxy)-1-hydroxy-propyl]-3-vinyl-phenyl dimethylcarbamate 
• 444646-67-7 Ethyl 3-(4-dimethylcarbamoyloxy-2-vinyl-phenyl)-3-hydroxypropionate 
• 444646-65-5 5-dimethylcarbamoyloxy-2-formyl-phenyl trifluoromethanesulfonate 
• 444646-66-6 dimethylcarbamic acid 4-formyl-3-vinylphenyl ester 
• 444646-64-4 4-formyl-3-hydroxy-phenyl dimethylcarbamate 

Downstream Products

• 649722-95-2 7-dimethylcarbamoyloxy-1-[2-(4-nitro-phenoxy)-ethyl]-5-vinyl-1,3-dihydro-benzo[c]azepine-2-carboxylic acid tert-butyl ester 
• 649722-87-2 7-dimethylcarbamoyloxy-1-[2-(4-nitrophenoxy)ethyl]-5-oxo-1,3,4,5-tetrahydrobenzo[c]azepine-2-carboxylic acid tert-butyl ester 
• 649723-02-4 dimethyl-carbamic acid 5-(4-chloro-phenyl)-1-[2-(4-nitro-phenoxy)-ethyl]-2,3-dihydro-1H-benzo[c]azepin-7-yl ester 
• 649722-92-9 7-dimethylcarbamoyloxy-5-methyl-1-[2-(4-nitro-phenoxy)-ethyl]-1,3-dihydro-benzo[c]azepine-2-carboxylic acid tert-butyl ester 
• 649723-09-1 dimethyl-carbamic acid 1-[2-(4-nitro-phenoxy)-ethyl]-5-thiophen-2-yl-2,3-dihydro-1H-benzo[c]azepin-7-yl ester 
• 649722-77-0 dimethylcarbamic acid 1-[2-(4-nitrophenoxy)ethyl]-2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl ester 
• 649722-85-0 7-dimethylcarbamoyloxy-1-(2-hydroxyethyl)-5-oxo-1,3,4,5-tetrahydrobenzo[c]azepine-2-carboxylic acid tert-butyl ester 
• 649722-62-3 dimethylcarbamic acid 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-1H-benzo[c]azepin-7-yl ester 
• 649722-79-2 dimethylcarbamic acid 1-[2-(4-chlorophenoxy)ethyl]-2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl ester 

Relevant academic research and scientific papers

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

Alzheimer's disease (AD) has been treated with acetylcholinesterase (AChE) inhibitors such as donepezil. However, the clinical usefulness of AChE inhibitors is limited mainly due to their adverse peripheral effects. Depression seen in AD patients has been treated with serotonin transporter (SERT) inhibitors. We considered that combining SERT and AChE inhibition could improve the clinical usefulness of AChE inhibitors. In a previous paper, we found a potential dual inhibitor, 1, of AChE (IC50=101 nM) and SERT (IC50=42 nM), but its AChE inhibition activity was less than donepezil (IC50=10 nM). Here, we report the conformationally restricted (R)-18a considerably enhanced inhibitory activity against AChE (IC50=14 nM) and SERT (IC50=6 nM).

BENZYLAMINE ANALOGUE

A compound of the formula (I): [wherein R1 represents a C1-C6 alkyl group etc., R2 and R3 are the same or different and represent a hydrogen atom etc., Ra represents a C1-C6 alkyl group etc., Arom represents an aryl group etc., A represents a C1-C6 alkylene group, E represents a single bond, an oxygen atom, a sulfur atom etc., X1 and X2 are the same or different and represent an oxygen atom or a sulfur atom] or a pharmacologically acceptable salt or ester thereof.